Table 1.
Baseline clinical characteristics of patients with COVID-19 vaccine–associated myocarditis (n = 20)
| Baseline clinical characteristics | |
|---|---|
| Age, y | 23.1 (20.3-29.4) |
| Male sex | 17 (85) |
| BMI, kg/m2 | 25 (23.2-27.6) |
| Diabetes | 0 (0) |
| Hypertension | 0 (0) |
| Dyslipidemia | 0 (0) |
| Current smoker | 0 (0) |
| Presenting symptomatology | |
| Chest pain | 19 (95) |
| Dyspnea | 2 (10) |
| Myalgias | 1 (5) |
| Sweating | 1 (5) |
| Epigastric discomfort | 1 (5) |
| Hospitalised | 18 (90) |
| CCU admission | 3 (15) |
| In-hospital clinical complications | |
| Hypotension | 0 (0) |
| Heart failure | 0 (0) |
| Respiratory failure/Intubation | 0 (0) |
| Atrial arrhythmia | 0 (0) |
| Ventricular arrhythmia | 0 (0) |
| Length of hospital stay, d | 3 (2-3) |
| Peak high-sensitivity troponin T, ng/L | 958 ± 627 |
| Peak NT-proBNP, ng/L (n = 4) | 576 (211-931) |
| Peak CRP, mg/L | 35.0 ± 24.1 |
| Leukocytosis (WBC > 11,000 per mm3) | 1 (5) |
| ECG at presentation | |
| Normal | 9 (45) |
| ST-segment elevation (diffuse or regional) | 11 (55) |
| PR depression | 4 (20) |
| Coronary artery angiography | |
| Abnormal | 0 (0) |
| Normal | 2 (10) |
| Not performed | 18 (90) |
| Medications at discharge | |
| Colchicine | 19 (95) |
| NSAIDs | 15 (75) |
| Steroids | 0 (0) |
| ACEi | 5 (25) |
| Beta-blocker | 4 (20) |
| Spironolactone | 1 (5) |
Values are presented as median (IQR), n (%), or mean ± SD.
ACEi, angiotensin-converting enzyme inhibitor; CCU, coronary care unit; CMR, cardiac magnetic resonance; CRP, C-reactive protein; ECG, electrocardiography; NT-proBNP, N-terminal pro–B-type natriuretic peptide; WBC, white blood cell count.